These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33325691)

  • 1. Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators.
    An S; Kim G; Kim HJ; Ahn S; Kim HY; Ko H; Hyun YE; Nguyen M; Jeong J; Liu Z; Han J; Choi H; Yu J; Kim JW; Lee HW; Jacobson KA; Cho WJ; Kim YM; Kang KW; Noh M; Jeong LS
    J Med Chem; 2020 Dec; 63(24):16012-16027. PubMed ID: 33325691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Activity Relationships of Truncated 1'-Homologated Carbaadenosine Derivatives as New PPARγ/δ Ligands: A Study on Sugar Puckering Affecting Binding to PPARs.
    Hyun YE; An S; Kim M; Park IG; Yoon S; Javaid HMA; Vu TNL; Kim G; Choi H; Lee HW; Noh M; Huh JY; Choi S; Kim HR; Jeong LS
    J Med Chem; 2023 Apr; 66(7):4961-4978. PubMed ID: 36967575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacology of N
    Yu J; Ahn S; Kim HJ; Lee M; Ahn S; Kim J; Jin SH; Lee E; Kim G; Cheong JH; Jacobson KA; Jeong LS; Noh M
    J Med Chem; 2017 Sep; 60(17):7459-7475. PubMed ID: 28799755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
    An S; Yu J; Choi H; Ko H; Ahn S; Shin JC; Pyo JJ; Jeong LS; Noh M
    Bioorg Med Chem; 2020 Jan; 28(1):115226. PubMed ID: 31806266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 7. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and SAR of Natural-Product-Inspired RXR Agonists with Heterodimer Selectivity to PPARδ-RXR.
    Nakashima KI; Yamaguchi E; Noritake C; Mitsugi Y; Goto M; Hirai T; Abe N; Sakai E; Oyama M; Itoh A; Inoue M
    ACS Chem Biol; 2020 Jun; 15(6):1526-1534. PubMed ID: 32374156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.
    Li Z; Xu Y; Cai Z; Wang X; Ren Q; Zhou Z; Xie R
    Bioorg Chem; 2020 Jun; 99():103803. PubMed ID: 32251945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.